WallStSmart
STRO

Sutro Biopharma

NASDAQ: STRO · HEALTHCARE · BIOTECHNOLOGY

$35.39
+2.02% today

Updated 2026-04-29

Market cap
$556.51M
P/E ratio
P/S ratio
5.43x
EPS (TTM)
$-22.49
Dividend yield
52W range
$7 – $36
Volume
0.2M

Sutro Biopharma (STRO) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2016201720182019202020212022202320242025
Revenue$59.73M$51.74M$38.42M$42.74M$42.72M$61.88M$67.77M$153.73M$62.04M$102.48M
Revenue growth (YoY)-13.4%-25.7%+11.2%-0.0%+44.8%+9.5%+126.8%-59.6%+65.2%
Cost of revenue$43.55M$51.90M$54.26M$65.61M$76.96M$9.77M$8.29M$6.82M$7.22M$7.32M
Gross profit$16.18M$-156000.00$-15.84M$42.74M$-34.24M$52.11M$59.48M$146.91M$54.83M$95.16M
Gross margin27.1%-0.3%-41.2%100.0%-80.1%84.2%87.8%95.6%88.4%92.9%
R&D$43.55M$54.64M$54.26M$65.61M$76.96M$104.40M$137.17M$180.43M$252.04M$166.42M
SG&A$14.82M$16.37M$21.38M$32.59M$36.82M$56.00M$59.54M$62.58M$48.45M$41.02M
Operating income$1.36M$-19.27M$-37.22M$-55.47M$-71.06M$-98.52M$-128.94M$-89.28M$-238.45M$-104.95M
Operating margin2.3%-37.2%-96.9%-129.8%-166.3%-159.2%-190.3%-58.1%-384.3%-102.4%
EBITDA$7.36M$-14.09M$-32.82M$-46.62M$-23.75M$-97.56M$-105.07M$-67.92M$-180.45M$-97.63M
EBITDA margin12.3%-27.2%-85.4%-109.1%-55.6%-157.7%-155.0%-44.2%-290.9%-95.3%
EBIT$1.70M$-19.08M$-37.36M$-51.39M$-28.05M$-102.40M$-113.36M$-74.73M$-187.67M$-104.95M
Interest expense$0.00$689000.00$1.60M$4.35M$3.97M$3.14M$3.35M$23.75M$31.07M$38.21M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$1.70M$-19.69M$-35.32M$-55.74M$-32.13M$-105.54M$-119.20M$-106.79M$-227.46M$-191.09M
Net income growth (YoY)-1256.8%-79.4%-57.8%+42.4%-228.5%-12.9%+10.4%-113.0%+16.0%
Profit margin2.8%-38.1%-91.9%-130.4%-75.2%-170.6%-175.9%-69.5%-366.6%-186.5%